ILMN posts
FeedPosted Oct 28th 2009 4:00PM by Jon Ogg (RSS feed)
Filed under: CIT Group (CIT), Palm Inc (PALM)

Maybe it was the dollar rising earlier, maybe it was poor housing data from a
drop in new home sales. Maybe they wanted more than a
marginally positive durable goods reading. Maybe it was that
oil inventory is back up. And then there is the notion that stocks have just gotten too far ahead of themselves and there were reports of a large strategist cutting GDP targets. But investors sold religiously today ahead of tomorrow's GDP figure.
Here were today's closing bell levels:
Dow 9,762.69 -119.48 (-1.21%)
S&P 500 1,042.63 -20.78 (-1.95%)
Nasdaq 2,059.61 -56.48 (-2.67%)
Top 10 Analyst CallsTop Day Trader AlertsContinue reading Closing Bell: The big giveback (ADUS, CIT, GRMN, ILMN, LVLT, PALM)
Posted Jul 12th 2009 3:00PM by Michael Shulman (RSS feed)
Filed under: Stocks to Buy
Do you think we're going to see more or less genomics research in coming years? End of discussion.
Illumina (NASDAQ: ILMN) is the leading provider of equipment for genomics researchers and its lead is growing. Buy and hold may be almost dead, but it certainly applies to ILMN. The stock has been trashed along with the market, but it's simply the best at what it does - and getting better.
Your best strategy for life-changing profits?
This is a stock to buy for the long term to use as a base for selling calls. Or, even better, you can write some credit spreads, as the calls have terrific premiums.
Don't miss the complete list of biotech stocks to buy now.
And for more ways to profit, check out:
Posted Mar 24th 2009 2:50PM by Steven Halpern (RSS feed)
Filed under: Newsletters, Stocks to Buy
"Illumina (NASDAQ: ILMN) makes the Genome Analyzer, which is the workhorse of the genetic medicine revolution," says growth expert Mike Cintolo in The Cabot Top Ten Report.
"The Illumina Genome Analyzer is used by genomic research centers, academic institutions, agriculture and livestock companies, pharmaceutical companies, clinical research organizations and biotechnology companies all over the world.
"In the fourth quarter of 2008, for example, the company launched the In? nium HD HumanCytoSNP-12 BeadChip, a 12 sample BeadChip priced as low as $125 per sample that enables researchers to analyze nearly 300,000 genetic markers per sample.
Continue reading Illumina (ILMN): Genetic workhorse
Posted Sep 18th 2008 11:30AM by Eric Buscemi (RSS feed)
Filed under: Analyst upgrades and downgrades, Whole Foods Market (WFMI), Amer Intl Group (AIG), Nortel Networks (NT), Analyst initiations, Lloyds TSB Group plc ADS (LYG)
Analyst upgrades:
- Baird upgraded Adtran (NASDAQ: ADTN) to Outperform from Neutral based on valuation, new product cycles, and confidence in 2H08 results.
- Morgan Stanley upgraded shares of Repsol (NYSE: REP) to Overweight from Equal Weight as they believe the potential sale to Sacyr Vallehermoso SA could lead to a restructuring.
- Stanford lifted National Oilwell Varco (NYSE: NOV) to Buy from Hold citing valuation. In addition, the firm, which set a target of $70, thinks most of the drop in commodity prices is now over.
- Ryanair (NASDAQ: RYAAY) was raised to Hold from Sell at Societe Generale.
- Ann Taylor (NYSE: ANN) was upgraded at Piper to Neutral from Sell.
- Goldman added Illinois Tool Works (NYSE: ITW) to the Conviction Buy List.
Analyst downgrades:
- Argus downgraded shares of Constellation Energy (NYSE: CEG) to Hold from Buy post-close given the volatility in the stock as they can no longer recommend CEG until concerns over its capital and liquidity are resolved. Shares were also downgraded to Hold from Buy at Citigroup.
- Collins Stewart downgraded Lloyds TSB Group (NYSE: LYG) to Hold from Buy following the acquisition of HBOS (OTC: HBOOY) as they expect short-term weakness in the stock.
Continue reading Analyst calls: NOC, RYAAY, ANN, CEG, LYG, NT, PLD, DPS, WFMI ...
Posted Jun 30th 2008 9:05AM by Timothy Sykes (RSS feed)
Filed under: General Electric (GE), General Motors (GM), Citigroup Inc. (C), Bank of America (BAC), , Amer Intl Group (AIG), Technical Analysis, Stocks to Buy, Stocks to Sell
No matter what any CEO, analyst, "guru", "market expert", strategist, fund manager, trader or message board poster says (few show all their trades and investments like me, nor are they up 60% in 2008, see details here), never try to catch a falling knife. Before I list all the current ones, I really have to pound it into your heads that buying these things in hugely uncertain -- and possibly disastrous -- times like these is not only dangerous, it's just plain irresponsible.
Here are some current falling knives:
Now, I don't want to hear those "I'm a long-term investor in blue-chip stocks" and "these are quality companies trading at discount prices"-type comments. While it's possible these stocks will bounce, the risk-reward ratio is downright awful here, just as its been for the past several months (as I've been warning in posts like this and this).
Continue reading The latest round of stocks to buy and to avoid
Posted Apr 1st 2008 12:35PM by Timothy Sykes (RSS feed)
Filed under: Google (GOOG), Apple Inc (AAPL), U.S. Steel (X), Technical Analysis, Las Vegas Sands (LVS), , , Stocks to Buy
Google (NASDAQ:
GOOG) this,
Apple Inc (NASDAQ:
AAPL) that, will
Lehman Brothers Holdings (NYSE:
LEH) follow
Bear Stearns (NYSE:
BSC) -- bleh, all hotly debated, all random market noise! Noise that you must learn to ignore.
The financial media -- envious of the fat profits generated by such entertainment-based businesses as
World Wrestling Entertainment Inc (NYSE:
WWE),
Las Vegas Sands Corp. (NYSE:
LVS) and
Wynn Resorts (NASDAQ:
WYNN) -- has brainwashed you into believing that in order to make money in the stock market, you must keep up to date with every single headline and development in the business world. Hogwash!
I have no problem with financial entertainment, but I do take issue with all these media outlets making their content out to be useful to investors. I've repeatedly echoed this theme in articles like
this and I don't expect this industry to change anytime soon, but I am going to keep preaching so you will better understand how low your chances of success are if you bet on the most popular -- hence the most efficient -- topics du jour. Unless you are George Soros or Warren Buffett or a few other wealthy elderly men, there is always somebody better informed and more intelligent than you are. Hence, you are always at a disadvantage.
Continue reading Ignore random market noise and focus on lesser known names
Posted Jan 29th 2008 11:05AM by Eric Buscemi (RSS feed)
Filed under: Home Depot (HD), Analyst initiations
MOST NOTEWORTHY: Home Depot, Seaspan and Pharmasset were today's noteworthy initiations:
- Morgan Keegan initiated Home Depot (NYSE: HD) with a Market Perform rating, citing valuation and the possibility that housing continues to deteriorate in 2008.
- Oppenheimer believes Seaspan (NASDAQ: SSW) is well positioned within the containership sector given its modern fleet profile and entrenched liner relationships. The firm assumed coverage with an Outperform rating and $32 target.
- JMP Securities initiated shares of Pharmasset (NASDAQ: VRUS) with a Market Outperform rating and $35 target and believes R7128 is evolving to be the premier product in hepatitis C. The firm expects a phase 2b trial evaluating R7128 in combination with standard of care to be initiated in 2H08 by partner Roche (OTC: RHHBY).
OTHER INITIATIONS:
- UBS started BioMarin (NASDAQ: BMRN) with a Neutral rating and $38 target.
- First Analysis initiated Ecolab (NYSE: ECL) with an Equal Weight rating.
- Illumina (NASDAQ: ILMN) was initiated with an Overweight rating at JP Morgan.
Posted Jan 10th 2008 4:15PM by Douglas McIntyre (RSS feed)
Filed under: After the bell, PepsiCo (PEP)
Illumina (NASDAQ: ILMN): Settles patent lawsuit with major rival Affymetrix (NASDAQ: AFFX). Shares trade up to $75.20 against 52-week low of $28.11.
Kinross Gold (NYSE: KGC): Price of gold and gold producers just keeps rising. Stock moves up to $22.86 from 52-week low of $9.87.
Yamana Gold (NYSE: AUY): Gold again. Rises to $16.30 from 52-week low of $8.40.
PepsiCo (NYSE: PEP): Soft-drinks sales aren't hurt by recessions, as far as anyone knows. Trades up to $79.79 from 52-week low of $61.89.
Douglas A. McIntyre is an editor at 247wallst.com.
Posted Sep 28th 2007 5:09PM by Barry Summerlin (RSS feed)
Filed under: Market matters, Personal finance, Stocks to Buy, Videos
Ready to make some serious money?
Wall Street Warrior Timothy Sykes isn't playing around -- he wants to make you rich. In this edition of
StockWatch: Between the Bells, the MSN Money host and author of
An American Hedge Fund: How I Made $2 Million as a Stock Operator & Created a Hedge Fund riffs -- and dances -- on a fistful of market strategies.
Tim has three daring tips for you. Digital content storage provider
Isilon Systems (NASDAQ:
ISLN) is sitting at an all-time low, more than 70% off its high at the start of the year, and looks priced to buy. Genetics biotech
Illumina Inc. (NASDAQ:
ILMN) is currently trading around $52; Tim sees ILMN climbing to $60. Sound a little
too risky? Tim suggests checking out
The Bruce Fund (
BRUFX), a mutual fund focusing on domestic common stock, convertible bonds and zero-coupon government bonds.
Considering a short-selling strategy? Tim calls out
China Precision Steel (NASDAQ:
CPSL), which has jumped more than three-fold in little more than a week and looks set to slide.
Jamba Juice (NASDAQ:
JMBA), meanwhile, is giving Tim fits -- revenues are up while same-store sales are slipping. He advises to stay away from JMBA.
Enjoy the clip, and let us know which of your favorite stock gurus you'd like to hear from in the next
StockWatch: Between the Bells!
Posted Jul 30th 2007 3:05PM by Larry Schutts (RSS feed)
Filed under: Earnings reports, Technical Analysis, Stocks to Buy
Innovative technologies now allow such detailed analysis of genetic variation and function that firms can work on the development of "personalized medicine". There is an outfit in San Diego that is in the front wave of firms designing the machines that make such research possible.
Illumina (NASDAQ: ILMN) is engaged in the development and marketing of tools for the analysis of genes. The firm sells systems that determine variation in genetic sequences, analyze which genes are active in a particular cell or group of cells, profile changes in genetic sequence function, and determine which proteins are present in cells and how they interact. Customers include biotechnology companies, research centers, and academic institutions.
The firm pleased investors last week, when it reported Q2 EPS of 16 cents and revenues of $84.5 million. Analysts had been expecting 13 cents and $77.7 million. Management also guided Q3 revenues to $88-92 million ($82.32M consensus) and FY07 revenues to $335-345 million ($323.05M consensus).
Continue reading Illumina: Investigating your genes
Posted Jun 14th 2007 10:37AM by Kevin Shult (RSS feed)
Filed under: Before the bell, Analyst upgrades and downgrades, Good news, Expedia Inc (EXPE), Oracle Corp (ORCL), Kohl's Corp (KSS)
MOST NOTEWORTHY: Steven Madden, Ltd (SHOO), Expedia, Inc (EXPE), Oracle Corp (ORCL) and Tim Horton's Inc (THI) round up today's noteworthy upgrade list:
- Steve Madden, Ltd (NASDAQ: SHOO) was upgraded to Buy from Neutral at Nollenberger as they believe Madden is well positioned going into the back half of 2007 with clean inventories and focused products.
- Matrix believes increasing marketing efforts and European growth are contributing to significant improvement in fundamental trends for Expedia Inc (NASDAQ: EXPE), and upgraded shares to Hold from Sell.
- Pacific Crest upgraded shares of Oracle Corp (NASDAQ: ORCL) to Outperform from Sector Perform to reflect improved channel checks and the probability of continued success.
- CIBC upgraded Tim Horton's (NYSE: THI) to Sector Outperformer from Sector Performer based on valuation...
OTHER UPGRADES:
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).Posted Jun 13th 2007 11:22AM by Kevin Shult (RSS feed)
Filed under: Before the bell, Analyst upgrades and downgrades, Good news, Blockbuster Inc 'A' (BBI), Bristol-Myers Squibb (BMY)
MOST NOTEWORTHY: Blockbuster Inc (BBI), Molson Coors Brewing Co (TAP), Illumina, Inc (ILMN), and ARM Holdings plc (ARMHY) were today's more noteworthy upgrades:
- Citigroup upgraded Blockbuster Inc (NYSE: BBI) to Buy from Hold based on valuation, improving box office visibility and their belief that the lower-priced online-only rental product will help improve costs.
- Molson Coors Brewing (NYSE: TAP) was upgraded to Buy from Neutral at UBS based on valuation, volume strength and pricing.
- Matrix believes strong demand for genetic analysis equipment is boosting profits for Illumina (NASDAQ: ILMN), upgrading shares to Strong Buy from Sell; Matrix sees upside to their Intrinsic Value Calculation of $50/share.
- ARM Holdings (NASDAQ: ARMHY) was upgraded to Overweight from Underweight at JP Morgan to reflect the strength in the high-end handset market...
OTHER UPGRADES:
- RBC Capital raised Sapient Corp (NASDAQ: SAPE) to Outperform from Sector Perform.
- Piper Jaffray upgraded shares of Omnicell, Inc (NASDAQ: OMCL) to Outperform from Market Perform.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).